参考文献/References:
[1].Galiè N,Humbert M,Vachiery JL,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC),International Society for Heart and Lung Transplantation (ISHLT)[J].?Eur Heart J,2016,37(1):67-119.
[2].Bradlow WM,Gibbs JS,Mohiaddin RH. Cardiovascular magnetic resonance in pulmonary hypertension[J].?J Cardiovasc Magn Reson,2012,14(1):6.
[3].吕致,董杨,陈玉成. 心脏磁共振在肺动脉高压右心室评价中的应用[J]. 心血管病学进展,2019,40(1):16-19.
[4].Hoeper MM,Humbert M,Souza R,et al. A global view of pulmonary hypertension[J]. Lancet Respir Med,2016,4(4):306-322.
[5].Jing ZC,Xu XQ,Han ZY,et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension[J]. Chest,2007,132(2):373-379.
[6].R,Dai LZ,Xie WP,et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era[J]. Chest,2011,140(2):301-309.
[7].Janicki JS,Brower GL. The role of myocardial fibrillar collagen in ventricular remodeling and function[J]. J Card Fail,2002,8(6 Suppl):S319-S325.
[8].Kusakari Y,Urashima T,Shimura D,et al. Impairment of excitation contraction coupling in right ventricular hypertrophied muscle with fibrosis induced by pulmonary artery banding[J]. PLoS One,2017,12(1):e0169564.
[9].Andersen S,Nielsen-Kudsk JE,Vonk Noordegraaf A,et al. Right ventricular fibrosis[J].?Circulation,2019,139(2):269-285.
[10].Burlew BS,Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction[J]. Herz,2002,27(2):92-98.
[11].Gulati A,Jabbour A,Ismail TF,et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. JAMA,2013,309(9):896-908.
[12].Flett AS,Hayward MP,Ashworth MT,et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans[J]. Circulation,2010,122(2):138-144.
[13].Pagano JJ,Chow K,Khan A,et al. Reduced right ventricular native myocardial T1 in Anderson-Fabry disease: comparison to pulmonary hypertension and healthy controls[J]. PLoS One,2016,11(6):e0157565.
[14].Patel RB,Li E,Benefield BC,et al. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension[J]. ESC Heart Fail,2020,7(1):253-263.
[15].Reiter U,Reiter G,Kovacs G,et al. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics[J]. Eur Radiol,2017,27(1):157-166.
[16].Swift AJ,Rajaram S,Condliffe R,et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry[J]. J Cardiovasc Magn Reson,2012,14(1):40.
[17].Saunders LC,Johns CS,Stewart NJ,et al. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension[J]. J Cardiovasc Magn Reson,2018,20(1):78.
[18].Sanz J,Dellegrottaglie S,Kariisa M,et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension[J]. Am J Cardiol,2007,100(4):731-735.
[19].Roller FC,Wiedenroth C,Breithecker A,et al. Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension[J]. Eur Radiol,2017,27(5):1980-1991.
[20].Wang J,Zhao H,Wang Y,et al. Native T1 and T2 mapping by cardiovascular magnetic resonance imaging in pressure overloaded left and right heart diseases[J]. J Thorac Dis,2018,10(5):2968-2975.
[21].Shehata ML,Lossnitzer D,Skrok J,et al. Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics,right ventricular function,and remodeling[J]. AJR Am J Roentgenol,2011,196(1):87-94.
[22].Spruijt OA,Vissers L,Bogaard HJ,et al. Increased native T1-values at the interventricular insertion regions in precapillary pulmonary hypertension[J]. Int J Cardiovasc Imaging,2016,32(3):451-459.
[23].Chen YY,Yun H,Jin H,et al. Association of native T1 times with biventricular function and hemodynamics in precapillary pulmonary hypertension[J]. Int J Cardiovasc Imaging,2017,33(8):1179-1189.
[24].Shiina Y,Taniguchi K,Nagao M,et al. The relationship between extracellular volume fraction in symptomatic adults with tetralogy of Fallot and adverse cardiac events[J]. J Cardiol,2020,75(4):424-431.
[25].Rain S,Handoko ML,Trip P,et al. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension[J]. Circulation,2013,128(18):2016-2025,1-10.
[26].Tello K,Dalmer A,Axmann J,et al. Reserve of right ventricular-arterial coupling in the setting of chronic overload[J]. Circ Heart Fail,2019,12(1):e005512.
[27].Freed BH,Gomberg-Maitland M,Chandra S,et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension[J]. J Cardiovasc Magn Reson,2012,14(1):11.
[28].Swift AJ,Rajaram S,Capener D,et al. LGE patterns in pulmonary hypertension do not impact overall mortality[J]. JACC Cardiovasc Imaging,2014,7(12):1209-1217.
[29].Sato T,Tsujino I,Ohira H,et al. Paradoxical interventricular septal motion as a major determinant of late gadolinium enhancement in ventricular insertion points in pulmonary hypertension[J]. PLoS One,2013,8(6):e66724.
[30].Roller FC,Kriechbaum S,Breithecker A,et al. Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty[J]. Eur Radiol,2019,29(3):1565-1573.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(2):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]韦余 胡科 温钞麟 邓玮.骨髓间充质干细胞干预心肌纤维化的增效措施[J].心血管病学进展,2019,(5):774.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.027]
Wei YuHu KeWen Chao LinDeng Wei.Synergistic Measures of Bone Marrow Mesenchymal Stem Cells in Intervention of Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2019,(2):774.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.027]
[5]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(2):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[6]孙敬辉 于永慧 王承龙.心肌纤维化研究的新领域——长链非编码RNA[J].心血管病学进展,2019,(9):1233.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.012]
SUN JinghuiYU YonghuiWANG Chenglong.Long No-Coding RNAA New Field of Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2019,(2):1233.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.012]
[7]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[8]位晨晨,钟明.糖尿病心肌病的发病机制[J].心血管病学进展,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
WEI Chenchen,ZHONG Ming.Pathogenesis of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
[9]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[10]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(2):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]